Mabwell (Shanghai) Bioscience Co., Ltd.: history, ownership, mission, how it works & makes money

Founded in 2017, Mabwell Bioscience Co., Ltd. burst onto the biopharmaceutical scene with a clear growth trajectory-listing on the Shanghai STAR Market under stock code 688062 in January 2022 after raising RMB 3.477 billion by issuing 99.9 million shares at RMB 34.80 each-and since then has secured strategic deals like the December 2022 licensing with Binnopharm for biosimilars 9MW0113, 9MW0321 and 9MW0311 in Russia/EAEU, a June 2025 exclusive IL-11 therapeutic collaboration with Calico (covering Phase I 9MW3811), a September 2025 joint venture Kalexo Bio with Aditum to advance dual-target siRNA 2MW7141 for lipid management, and the November 2025 first U.S. patient dosing in the Phase II study of anti-ST2 mAb 9MW3011; guided by Chairman and CEO Dr. Liu Datao and a mission to 'Explore Life, Benefit Health' with a vision of Innovation, from Ideas to Reality, Mabwell operates a vertically integrated model-R&D through GMP-compliant manufacturing overseen to NMPA/FDA/EMA standards-and monetizes its work via product sales, licensing fees and royalties across a pipeline of 14 products (10 novel candidates and 4 biosimilars) spanning oncology, immunology, metabolic and other therapeutic areas, while leveraging strategic partnerships and national scientific projects to expand commercialization and global clinical development.

Mabwell Bioscience Co., Ltd. (688062.SS): Intro

Mabwell Bioscience Co., Ltd. (688062.SS) is a Shanghai-based biopharmaceutical company focused on developing and commercializing biologics and novel RNA therapies targeting oncology, immunology, metabolic and age-related diseases. Since its founding in 2017 the company has progressed from antibody biosimilars to innovative first-in-class and best-in-class therapeutics with global development and commercialization aspirations. More on its background and strategy can be found here: Mabwell (Shanghai) Bioscience Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

• Founded: 2017 (Shanghai, China)
• Stock exchange listing: Shanghai STAR Market (Ticker: 688062.SS)
• IPO: January 2022 - proceeds ~RMB 3.477 billion from 99.9 million shares at RMB 34.80/share

Ownership & Capital Structure

• Publicly listed on Shanghai STAR Market (688062.SS) - free float following IPO in 2022
• IPO proceeds (~RMB 3.477 billion) used for R&D, manufacturing capacity and global clinical development
• Typical ownership mix: founders/management, institutional investors, and public shareholders post-IPO (specific major shareholders vary over time per regulatory filings)

Mission & Strategic Focus

• Mission: develop accessible, high-quality biologics and next-generation RNA/antibody therapeutics addressing oncology, immune, metabolic and aging-related diseases
• Strategy: advance both biosimilars for near-term commercialization and innovative first-in-class assets for global markets
• Key tactical priorities: build clinical-stage pipeline, secure regional licensing partnerships, expand manufacturing and enter Western regulatory pathways

How It Works - R&D, Platforms & Pipeline

Mabwell operates integrated discovery, preclinical and clinical development with internal biologics and RNA platforms plus partnerships for regional development and specialized indications.

Business Model - How Mabwell Makes Money

• Direct product sales - biosimilars and, eventually, proprietary biologics in territories where Mabwell commercializes directly or via licensees
• Out-licensing & regional deals - upfront payments, development & regulatory milestones, royalties (e.g., Binnopharm deal for Russia/EAEU)
• Collaborative R&D & licensing with biotechs and research institutes - option/license fees and milestone payments (e.g., Calico IL-11 collaboration)
• Equity and JV value creation - spinouts/joint ventures (Kalexo Bio with Aditum) that can unlock partner investments and future exit value
• Government grants and public funding for innovative R&D (common in Chinese biotech ecosystem)

Key Financial & Operational Metrics (selected)

Partnerships & Geographic Reach

• Binnopharm Group - exclusive rights in Russia & Eurasian Economic Union for three biosimilars (Dec 2022)
• Calico Life Sciences - exclusive licensing for IL-11 directed therapeutics, including 9MW3811 (Jun 2025)
• Aditum Bio - co-founder of Kalexo Bio to advance 2MW7141 (Sep 2025)
• U.S. clinical operations - first patient dosed in U.S. Phase II trial for 9MW3011 (Nov 2025)

Selected Clinical & Commercial Milestones (timeline)

Mabwell Bioscience Co., Ltd. (688062.SS): History

• Listing: Shanghai Stock Exchange - STAR Market (ticker: 688062)
• Leadership: Dr. Liu Datao serves as Chairman and CEO, directing strategy and operations
• Shareholder base: diverse mix of institutional and individual investors; specific major-holder percentages are not publicly disclosed
• Strategic partnerships: includes a licensing agreement with Binnopharm Group to broaden market reach and product offerings

• Ownership structure: publicly traded with centralized executive management and a board comprising executive and non-executive members to balance oversight and management
• Organizational focus: dedicated teams for research & development, manufacturing, and commercialization to support product pipeline progression and market entry
• Governance note: exact shareholding percentages for major shareholders are not typically disclosed on the STAR Market and are not available in public filings

Mabwell Bioscience Co., Ltd. (688062.SS): Ownership Structure

• Mission: 'Explore Life, Benefit Health' - prioritize translational biopharmaceutical innovation to improve patient outcomes.
• Vision: 'Innovation, from Ideas to Reality' - convert scientific concepts into clinical and commercial products.
• Core values: integrity, collaboration, excellence; emphasis on patient-centric development and global access.

• Major shareholders: mix of founders, founding management, institutional investors and employee equity pools-founder/management and institutional stakes typically account for the largest blocks to maintain strategic control.
• Board and committees: scientific oversight, audit, and compensation committees support regulatory-compliant development and commercialization pathways.
• Financing strategy: combination of public equity, strategic partnerships, licensing milestones, and targeted financing to fund clinical programs.

• R&D pipeline to value: internal discovery and IND-enabling studies feed biologics and biosimilar candidates into clinical trials; successful trials enable licensing, out-licensing, or in-house commercialization.
• Partnerships & licensing: milestone and royalty deals provide non-dilutive cash and de-risked pathways to global markets.
• Manufacturing and COGS: outsourced and in-house manufacturing mixes to manage costs as biologic candidates progress.

Mabwell Bioscience Co., Ltd. (688062.SS): Mission and Values

• Core mission: advance novel biologics and biosimilars from target discovery to commercial supply to broaden patient access.
• Values: scientific rigor, regulatory compliance, manufacturing excellence, and strategic partnership.
• Operational focus: integrate R&D, CMC (chemistry, manufacturing and controls), and commercialization to shorten timelines and control costs.

• Discovery & early research: target identification, lead generation and antibody engineering performed in-house to produce drug candidates with optimized druggability.
• Preclinical & clinical development: translational pharmacology, IND-enabling studies and phased clinical trials managed by internal teams and external CROs.
• Manufacturing transformation: GMP-compliant biologics production scaled from pilot to commercial batches under NMPA/FDA/EMA-aligned standards.
• Commercialization & licensing: in-market launches, partner licensing and regional collaborations to accelerate uptake and expand geographies.

• Facilities: in-house manufacturing suites designed for monoclonal antibodies and biologics production.
• Quality standards: facilities and processes compliant with international GMP as regulated by NMPA, FDA and EMA expectations to support global filings and exports.
• Scale strategy: integrated CMC capability designed to transition candidates from lab scale to commercial supply, reducing reliance on third‑party CDMOs.

• Notable alliances: agreements and collaborations with Binnopharm Group and Calico Life Sciences to co-develop or license programs and access complementary capabilities.
• Deal objectives: broaden product portfolio, share development risk, and access additional markets and technologies.

• Product sales: commercial revenues from approved biologics and biosimilars once launched in domestic and international markets.
• Licensing & milestones: upfronts, R&D milestones and royalties from out‑licensing agreements and partnerships.
• Manufacturing services: fee income from contract manufacturing or tech‑transfer services for partners when facilities have available capacity.
• Collaborative research funding: co‑development financing and research support from strategic partners.

Mabwell Bioscience Co., Ltd. (688062.SS): How It Works

• Primary business activities: discovery & preclinical research, clinical development, commercial manufacturing, marketing and licensing.
• Therapeutic focus areas: oncology (solid tumors, hematologic malignancies), autoimmune and inflammatory diseases, metabolic disorders.
• Key assets: proprietary monoclonal antibodies, biosimilar candidates, ADC platform and biologics manufacturing capacity.

• Target discovery & validation → antibody engineering and candidate selection.
• Preclinical testing and IND-enabling studies using internal labs and CRO partnerships.
• Clinical development (Phase I-III) supported by in-house clinical operations and external collaborators.
• Manufacturing scale-up in GMP facilities for both proprietary drugs and commercial biosimilars.
• Commercialization via direct sales in China, licensing/partnering for other regions, and royalty streams from out-licensing.

• Product sales - revenues from marketed biologics and commercialized biosimilars in domestic markets.
• Licensing & royalties - exclusive licensing agreements (for example, a noted collaboration with Binnopharm Group granting regional development/marketing rights) generate upfront payments, milestones and ongoing royalties.
• Contract development & manufacturing (CDMO)-style income - manufacturing services for partners and revenue from fill/finish or large-scale biologics production runs.
• R&D grants & public programs - participation in national major scientific and technological projects provides direct funding, subsidies and preferential policies that de-risk R&D spend.
• Strategic collaborations - co-development deals and regional commercialization partnerships that layer milestone payments onto long-term revenue streams.

• Product approvals and successful launches directly increase product-sales line items; payor inclusion and hospital procurement cycles are key to adoption speed.
• Licensing deals such as with Binnopharm provide non-dilutive upfront payments, success-based milestones and percentage royalties that smooth revenue volatility.
• Participation in national-level scientific projects both funds specific programs and can accelerate regulatory interactions, indirectly supporting faster time-to-market.
• International expansion and out-licensing accelerate revenue diversification beyond China but depend on partner execution and regulatory approvals in target markets.
• Manufacturing services and fill/finish contracts monetize excess capacity and provide countercyclical revenue during clinical-stage cycles.

• Pipeline prioritization - advancing candidates with clear regulatory pathways and strong commercial potential.
• Partnerships - selective licensing (territory- or indication-specific) to capture upfront and milestone economics while sharing development risk.
• Cost control - managing R&D spend and optimizing manufacturing utilization to improve gross margins as product sales scale.
• Regulatory strategy - leveraging expedited pathways, domestically and in target export markets, to accelerate launches and payer access.

• Binnopharm Group licensing: exclusive rights in specified regions for certain Mabwell candidates, structured as upfront payment + development milestones + tiered royalties on sales, providing a blended revenue stream beyond direct sales.

• Clinical progression milestones - achievement of Phase II/III readouts materially affects valuation and potential milestone receipts.
• Manufacturing utilization rate - higher utilization reduces per-unit costs and increases CDMO revenue potential.
• Regulatory approvals and NMPA reimbursement listings - essential to scale domestic product revenue.

Mabwell Bioscience Co., Ltd. (688062.SS): How It Makes Money

• Core revenue streams: commercial sales of marketed biologics (primarily monoclonal antibodies and biosimilars), licensing income, and CDMO/technology service fees.
• R&D-driven value capture: milestone payments and royalties from international licensing deals and co-development agreements.
• Partnership leverage: strategic alliances amplify market reach and provide non-dilutive funding through upfronts and milestones.

• Mabwell holds a meaningful position in the Chinese biopharmaceutical market driven by biosimilar and innovative antibody launches and a growing CDMO footprint.
• Strategic partnerships - notably with Binnopharm Group for regional commercialization and with Calico Life Sciences on discovery/early‑stage collaboration - have expanded product reach and bolstered R&D capabilities.
• Internationalization: licensing agreements and active clinical trials in APAC, Europe and North America position Mabwell as an emerging global competitor.
• Pipeline strength: roughly a dozen candidates across oncology, autoimmune and metabolic indications, with multiple assets in late‑stage development expected to drive medium‑term revenue upside.
• Financial drivers: topline growth will depend on successful commercialization of recent approvals, royalty streams from out‑licensing, and positive Phase II/III outcomes; operating profitability is improving as sales scale and R&D is optimized.
• Future focus: expand global footprint, convert pipeline assets into revenue-generating products, and monetize platform technologies via partnerships and CDMO contracts.

• Levers: successful Phase III readouts, new product launches, deeper commercial partnerships, scale-up of CDMO operations, and international regulatory approvals.
• Risks: clinical failures, pricing pressure for biosimilars, regulatory delays in foreign markets, and capital intensity of late‑stage trials.